1. Membrane Transporter/Ion Channel
  2. P2X Receptor

P2X Receptor

P2X receptors are a family of cation-permeable ligand gated ion channels that open in response to the binding of extracellular adenosine 5'-triphosphate (ATP). They belong to a larger family of receptors known as the purinergic receptors. P2X receptors are present in a diverse array of organisms including humans, mouse, rat, rabbit, chicken, zebrafish, bullfrog, fluke, and amoeba. seven separate genes coding for P2X subunits have been identified, and named to as P2X1 through P2X7. The pharmacology of a given P2X receptor is largely determined by its subunit makeup. Different subunits exhibit different sensitivities to purinergic agonists and antagonists. Of continuing interest is the fact that some P2X receptors (P2X2, P2X4, human P2X5, and P2X7) exhibit multiple open states in response to ATP, characterized by a time-dependent increase in the permeabilities of large organic ions and nucleotide binding dyes.

P2X Receptor Related Products (14):

Cat. No. Product Name Effect Purity
  • HY-15488A
    A 438079 (hydrochloride) Antagonist
    A 438079 (hydrochloride) is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.
  • HY-13290
    KN-62 Antagonist
    KN-62 is a selective and potent inhibitor of calmodulin-dependent protein kinase II (CaMK-II) with IC50 of 0.9 μM, KN-62 also displays noncompetitive antagonism at P2X7 receptors in HEK293 cells, with an IC50 value of approximately 15 nM.
  • HY-50697
    A-740003 Antagonist
    A-740003 is a potent, selective and competitive P2X7 receptor antagonist with IC50 values are 18 and 40 nM for rat and human P2X7 receptors, respectively.
  • HY-B0345A
    ATP disodium salt Agonist
    ATP Disodium salt is a P2 purinoceptor agonist.
  • HY-14483
    AF-353 Antagonist
    AF-353 is a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist, inhibits human and rat P2X3 (pIC50= 8.0).
  • HY-19427A
    AZD9056 hydrochloride Inhibitor
    AZD9056 is a selective orally active inhibitor of P2X7 which plays a significant role in inflammation and pain-causing diseases.
  • HY-15568
    A-317491 Antagonist
    A-317491 is a non-nucleotide P2X3 and P2X2/3 receptor antagonist, which inhibits calcium flux mediated by the receptors.
  • HY-15568A
    A-317491 sodium salt hydrate Antagonist
    A-317491 is a non-nucleotide P2X3 and P2X2/3 receptor antagonist, which inhibits calcium flux mediated by the receptors.
  • HY-13954
    A 839977 Antagonist
    A-839977 is a novel and selective P2X7 antagonist; blocks BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors (IC50 values are 20, 42 and 150 nM respectively).
  • HY-15488
    A 438079 Antagonist
    A 438079 is a competitive P2X7 receptor antagonist (pIC50 = 6.9 for the inhibition of Ca2+ influx in the human recombinant P2X7 cell line).
  • HY-100483
    A-804598 Antagonist
    A-804598 is a novel, competitive, and selective P2X7 receptor antagonist with IC50 of 10 nM, 9 nM and 11 nM in rat, mouse and human P2X7 receptors respectively.
  • HY-15469
    GW791343 dihydrochloride Inhibitor
    GW791343 2Hcl is a P2X7 allosteric modulator; exhibits species-specific activity and acts as a negative allosteric modulator of human P2X7 (pIC50 = 6.9 - 7.2).
  • HY-N0383
    Lappaconitine Inhibitor
    Lappaconitine, isolated from Aconitum sinomontanum Nakai, was characterized as analgesic principle.
  • HY-15470
    GW791343 trihydrochloride Inhibitor
    GW791343 3Hcl is a P2X7 allosteric modulator; exhibits species-specific activity and acts as a negative allosteric modulator of human P2X7 (pIC50 = 6.9 - 7.2).